CA2156512C - Traitement de la calvitie d'origine androgene, a l'aide d'oligomeres antisens - Google Patents

Traitement de la calvitie d'origine androgene, a l'aide d'oligomeres antisens Download PDF

Info

Publication number
CA2156512C
CA2156512C CA002156512A CA2156512A CA2156512C CA 2156512 C CA2156512 C CA 2156512C CA 002156512 A CA002156512 A CA 002156512A CA 2156512 A CA2156512 A CA 2156512A CA 2156512 C CA2156512 C CA 2156512C
Authority
CA
Canada
Prior art keywords
oligomer
oligomers
rna
sequence
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002156512A
Other languages
English (en)
Other versions
CA2156512A1 (fr
Inventor
Mary Ellen Harper
Tod Mitchell Woolf
Lyle John Arnold Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc filed Critical Genta Inc
Publication of CA2156512A1 publication Critical patent/CA2156512A1/fr
Application granted granted Critical
Publication of CA2156512C publication Critical patent/CA2156512C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/99—Oxidoreductases acting on the CH-CH group of donors (1.3) with other acceptors (1.3.99)
    • C12Y103/99005—3-Oxo-5alpha-steroid 4-dehydrogenase (acceptor) (1.3.99.5), i.e. steroid-5alpha-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
CA002156512A 1993-02-19 1994-02-18 Traitement de la calvitie d'origine androgene, a l'aide d'oligomeres antisens Expired - Fee Related CA2156512C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1954393A 1993-02-19 1993-02-19
US08/019,543 1993-02-19
PCT/US1994/001748 WO1994018835A1 (fr) 1993-02-19 1994-02-18 Traitement de la calvitie associee aux androgenes au moyen d'oligomeres antisens

Publications (2)

Publication Number Publication Date
CA2156512A1 CA2156512A1 (fr) 1994-09-01
CA2156512C true CA2156512C (fr) 2002-11-19

Family

ID=21793773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002156512A Expired - Fee Related CA2156512C (fr) 1993-02-19 1994-02-18 Traitement de la calvitie d'origine androgene, a l'aide d'oligomeres antisens

Country Status (6)

Country Link
EP (1) EP0684764A4 (fr)
JP (1) JPH08506961A (fr)
AU (1) AU692148B2 (fr)
CA (1) CA2156512C (fr)
IL (1) IL108712A0 (fr)
WO (1) WO1994018835A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739553B1 (fr) * 1995-10-06 1998-01-02 Oreal Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
WO1997038728A1 (fr) * 1996-04-15 1997-10-23 Dyad Pharmaceutical Corporation Therapie d'association de l'alopecie chez les hommes avec oligonucleotides antisens et minoxidil
US6489163B1 (en) * 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
AU753270B2 (en) * 1998-05-21 2002-10-10 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
EP1469009A2 (fr) * 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Compositions et procédés pour la délivrance non parentérale d'oligonucléotides
IT1318379B1 (it) * 2000-03-08 2003-08-25 Ira Srl Composizione cosmetica o farmaceutica utile per inibire o ritardarel'alopecia umana mediante applicazione topica della composizione.
AU2001253487A1 (en) * 2000-04-13 2001-10-30 Millennium Pharmaceuticals, Inc. 23155 novel protein human 5-alpha reductases and uses therefor
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US20080207545A1 (en) * 2003-10-21 2008-08-28 Hoke Glenn D Methods and Compositions for Treating 5Alpha-Reductase Type 1 and Type 2 Dependent Conditions
DE102004025881A1 (de) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
JP6768253B2 (ja) * 2015-10-09 2020-10-14 井上　肇 対象者の男性型脱毛症に関する情報を取得する方法
EP3497114B1 (fr) * 2016-08-08 2024-10-16 Olipass Corporation Oligonucléotides antisens du récepteur des androgènes
EP3526239B1 (fr) * 2016-10-11 2021-11-03 Olipass Corporation Oligonucléotides antisens hif 1-alpha

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507911A (ja) * 1991-05-31 1994-09-08 ジンタ・インコーポレイテッド 中性オリゴマーを経皮投与するための組成物及び供給系
JPH08504103A (ja) * 1992-12-08 1996-05-07 ジンタ・インコーポレイテッド 新しいモチーフを用いた３重らせん複合体の形成

Also Published As

Publication number Publication date
AU692148B2 (en) 1998-06-04
IL108712A0 (en) 1994-05-30
EP0684764A1 (fr) 1995-12-06
JPH08506961A (ja) 1996-07-30
EP0684764A4 (fr) 1997-10-22
AU6243794A (en) 1994-09-14
CA2156512A1 (fr) 1994-09-01
WO1994018835A1 (fr) 1994-09-01

Similar Documents

Publication Publication Date Title
CA2156512C (fr) Traitement de la calvitie d'origine androgene, a l'aide d'oligomeres antisens
US5877160A (en) Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
EP0198893B1 (fr) Modification de la croissance pileuse
JP5237247B2 (ja) 新規オリゴヌクレオチド、および脱色剤として、メラニン色素合成に含まれる酵素の発現を調節するオリゴヌクレオチドの使用
US20130324586A1 (en) Inhibition of Hairless Protein mRNA
US5994319A (en) Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil
JP5208740B2 (ja) 脱色素剤としての新規チロシナーゼ特異性アンチジーンオリゴヌクレオチド
JP2011254826A (ja) 皮膚脱色素剤としての、プロテイン−キナーゼｃベータ−１アイソフォームの発現を調節するヌクレオチド及びその使用
DE19750702A1 (de) Antisense Oligonucleotide gegen Tenascin zur Behandlung von Vitiligo
CA2449822C (fr) Limitation de la repousse des cheveux
US5609858A (en) Method for treatment of androgenic alopecia
JP5599615B2 (ja) チロシナーゼ関連タンパク質−１（ｔｒｐ−１）をコードする遺伝子と相互作用してその発現を調節する新規オリゴヌクレオチド、および該オリゴヌクレオチドの脱色素剤としての使用
JP2005510204A (ja) ヘアレス蛋白質発現を阻害するための核酸及びその使用方法
DE10141443B4 (de) Verwendung von molekularbiologisch hergestellten, nicht-viralen Wirkstoffen zur Behandlung der Akne
KR102666470B1 (ko) 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
KR102666469B1 (ko) 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
KR102647264B1 (ko) 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed